Skip to content
2000
Volume 24, Issue 2
  • ISSN: 2211-3525
  • E-ISSN: 2211-3533

Abstract

Introduction

Patients with indwelling medical devices and those with impaired immune systems are the primary targets of methicillin-resistant (MRSE), a common infection linked to healthcare. Its gram-positive nature and ability to develop biofilms make it the causative agent of more than 30% of coagulase-negative (CoNS) infections.

Objective

This narrative review provides an overview of the epidemiology, mechanisms of resistance, clinical significance, and emerging treatment strategies for MRSE, with a particular focus on recent advancements in infection prevention and control.

Methods

A comprehensive narrative review of literature published between 2010 and 2024 was conducted using PubMed, Scopus, and Web of Science. MeSH terms and free text keywords that would be relevant to the study have been used accordingly to identify studies of MRSE epidemiology, resistance mechanisms, infection control, and therapeutic interventions.

Results and Discussion

With outbreaks connected to clonal complexes CC5 and CC8, the incidence of MRSE has risen by about 25% in North America and Europe and by 35% in Asia over the last ten years. Incident rates are close to 40% among high-risk groups, especially those receiving immunosuppressive treatment or extended hospital stays. Methicillin resistance is caused by the mecA gene, which makes treatment more difficult. Dalbavancin and oritavancin are two examples of novel antimicrobials that have demonstrated clinical efficacy, lowering infection rates by as much as 20%. In high-risk environments, the use of improved infection control techniques has reduced transmission by about 15%. Antimicrobial peptides and bacteriophage-based treatments are two promising research directions.

Conclusion

Infection control in hospital settings is severely hampered by the increasing frequency and antibiotic resistance of MRSE. To lessen its clinical impact and enhance therapeutic results, more research and the application of strong infection control procedures are necessary.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/aia/10.2174/0122113525388954250603114510
2025-07-29
2026-03-09

  • From This Site

    /content/journals/aia/10.2174/0122113525388954250603114510
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. HaqueN. BariM.S. HaqueN. KhanR.A. HaqueS. KabirM.R. YasminT. Methicillin resistant Staphylococcus epidermidis.Mymensingh Med. J.2011202326331 21522111
     [Google Scholar]
  2. AsanteJ. HetsaB.A. AmoakoD.G. AbiaA.L.K. BesterL.A. EssackS.Y. Genomic analysis of antibiotic-resistant Staphylococcus epidermidis isolates from clinical sources in the Kwazulu-Natal Province, South Africa.Front. Microbiol.20211265630610.3389/fmicb.2021.656306 34421833
     [Google Scholar]
  3. BeckerK. HeilmannC. PetersG. Coagulase-negative Staphylococci.Clin. Microbiol. Rev.201427487092610.1128/CMR.00109‑13 25278577
     [Google Scholar]
  4. JukesL. MikhailJ. Bome-MannathokoN. HadfieldS.J. HarrisL.G. El-BouriK. DaviesA.P. MackD. Rapid differentiation of Staphylococcus aureus, Staphylococcus epidermidis and other coagulase-negative staphylococci and meticillin susceptibility testing directly from growth-positive blood cultures by multiplex real-time PCR.J. Med. Microbiol.201059121456146110.1099/jmm.0.023168‑0 20813851
     [Google Scholar]
  5. KlaschikS. LehmannL.E. SteinhagenF. BookM. MolitorE. HoeftA. StueberF. Differentiation between Staphylococcus aureus and coagulase-negative Staphylococcus species by real-time PCR including detection of methicillin resistants in comparison to conventional microbiology testing.J. Clin. Lab. Anal.201529212212810.1002/jcla.21739 24796889
     [Google Scholar]
  6. SunagarR. DeoreS.N. DeshpandeP.V. RizwanA. SannejalA.D. SundareshanS. RawoolD.B. BarbuddheS.B. JhalaM.K. BannalikarA.S. MugalikarD.M. KumariV.J. DhanalakshmiK. ReddyY.N. RaoP.P. BabraC. TiwariJ.G. MukkurT.K. CostantinoP. WetherallJ.D. IsloorS. HegdeN.R. Differentiation of Staphylococcus aureus and Staphylococcus epidermidis by PCR for the fibrinogen binding protein gene.J. Dairy Sci.20139652857286510.3168/jds.2012‑5862 23477820
     [Google Scholar]
  7. FosterT.J. Antibiotic resistance in Staphylococcus aureus. Current status and future prospects.FEMS Microbiol. Rev.201741343044910.1093/femsre/fux007 28419231
     [Google Scholar]
  8. HuemerM. Mairpady ShambatS. BruggerS.D. ZinkernagelA.S. Antibiotic resistance and persistence—Implications for human health and treatment perspectives.EMBO Rep.20202112e5103410.15252/embr.202051034 33400359
     [Google Scholar]
  9. Mlynarczyk-BonikowskaB. KowalewskiC. Krolak-UlinskaA. MaruszaW. Molecular mechanisms of drug resistance in Staphylococcus aureus.Int. J. Mol. Sci.20222315808810.3390/ijms23158088 35897667
     [Google Scholar]
  10. NarendrakumarL. ChakrabortyM. KumariS. PaulD. DasB. β-Lactam potentiators to re-sensitize resistant pathogens: Discovery, development, clinical use and the way forward.Front. Microbiol.202313109255610.3389/fmicb.2022.1092556 36970185
     [Google Scholar]
  11. TongS.Y.C. DavisJ.S. EichenbergerE. HollandT.L. FowlerV.G. Staphylococcus aureus infections: Epidemiology, pathophysiology, clinical manifestations, and management.Clin. Microbiol. Rev.201528360366110.1128/CMR.00134‑14 26016486
     [Google Scholar]
  12. OttoM. Staphylococcus epidermidis - The ‘accidental’ pathogen.Nat. Rev. Microbiol.20097855556710.1038/nrmicro2182 19609257
     [Google Scholar]
  13. SalehiM. Abdolhamid AngajiS. MosavariN. AhrabiM. SNP Scanning in mecA Gene for Methicillin-resistant Staphylococcus aureus.Iran. J. Biotechnol.2020183e2242 33850938
     [Google Scholar]
  14. BieloryL. LienK.W. BigelsenS. Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis.Drugs200565221522810.2165/00003495‑200565020‑00004 15631542
     [Google Scholar]
  15. HuebnerJ. GoldmannD.A. Coagulase-negative staphylococci: role as pathogens.Annu. Rev. Med.19995022323610.1146/annurev.med.50.1.223 10073274
     [Google Scholar]
  16. WisplinghoffH. BischoffT. TallentS.M. SeifertH. WenzelR.P. EdmondM.B. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study.Clin. Infect. Dis.200439330931710.1086/421946 15306996
     [Google Scholar]
  17. DiekemaD.J. PfallerM.A. SchmitzF.J. SmayevskyJ. BellJ. JonesR.N. BeachM. Survey of infections due to Staphylococcus species: Frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999.Clin. Infect. Dis.200132s2S114S13210.1086/320184 11320452
     [Google Scholar]
  18. BouchamiO. AchourW. MekniM.A. RoloJ. HassenA.B. Antibiotic resistance and molecular characterization of clinical isolates of methicillin-resistant coagulase-negative staphylococci isolated from bacteremic patients in oncohematology.Folia Microbiol. (Praha)201156212213010.1007/s12223‑011‑0017‑1 21431912
     [Google Scholar]
  19. AkinyemiK.O. AlabiS.A. TaiwoM.A. OmonigbehinE.A. Antimicrobial susceptibility pattern and plasmid profiles of pathogenic bacteria isolated from subjects with urinary tract infections in Lagos, Nigeria.Nig. Q. J. Hosp. Med.19971711
     [Google Scholar]
  20. SievertD.M. RicksP. EdwardsJ.R. SchneiderA. PatelJ. SrinivasanA. KallenA. LimbagoB. FridkinS. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010.Infect. Control Hosp. Epidemiol.201334111410.1086/668770 23221186
     [Google Scholar]
  21. KleinE.Y. MojicaN. JiangW. CosgroveS.E. SeptimusE. MorganD.J. LaxminarayanR. Trends in methicillin-resistant Staphylococcus aureus hospitalizations in the United States, 2010-2014.Clin. Infect. Dis.201765111921192310.1093/cid/cix640 29020322
     [Google Scholar]
  22. KlevensR.M. MorrisonM.A. NadleJ. PetitS. GershmanK. RayS. HarrisonL.H. LynfieldR. DumyatiG. TownesJ.M. CraigA.S. ZellE.R. FosheimG.E. McDougalL.K. CareyR.B. FridkinS.K. Invasive methicillin-resistant Staphylococcus aureus infections in the United States.JAMA2007298151763177110.1001/jama.298.15.1763 17940231
     [Google Scholar]
  23. KluytmansJ. van BelkumA. VerbrughH. Nasal carriage of Staphylococcus aureus: Epidemiology, underlying mechanisms, and associated risks.Clin. Microbiol. Rev.199710350552010.1128/CMR.10.3.505 9227864
     [Google Scholar]
  24. SiddiquiA.H. KoiralaJ. Methicillin-Resistant Staphylococcus aureus.StatPearls.Treasure IslandStatPearls Publishing202318
     [Google Scholar]
  25. ChoiS.W. LeeJ.C. KimJ. KimJ.E. BaekM.J. ParkS.Y. ParkS. ShinB.J. Prevalence and risk factors for positive nasal methicillin-resistant Staphylococcus aureus carriage among orthopedic patients in Korea.J. Clin. Med.20198563110.3390/jcm8050631 31072048
     [Google Scholar]
  26. Ponce-de-LeónA. Camacho-OrtizA. MacíasA.E. Landín-LariosC. Villanueva-WalbeyC. Trinidad-GuerreroD. López-JácomeE. Galindo-FragaA. Bobadilla-del-ValleM. Sifuentes-OsornioJ. Epidemiology and clinical characteristics of Staphylococcus aureus bloodstream infections in a tertiary-care center in Mexico City: 2003-2007.Rev. Invest. Clin.2010626553559 21416781
     [Google Scholar]
  27. IrekE.O. AmupitanA.A. ObadareT.O. AboderinA.O. A systematic review of healthcare-associated infections in Africa: An antimicrobial resistance perspective.Afr. J. Lab. Med.20187279610.4102/ajlm.v7i2.796 30568902
     [Google Scholar]
  28. GomesF. TeixeiraP. OliveiraR. Mini-review: Staphylococcus epidermidis as the most frequent cause of nosocomial infections: Old and new fighting strategies.Biofouling201430213114110.1080/08927014.2013.848858 24283376
     [Google Scholar]
  29. Martínez-SantosV.I. Torres-AñorveD.A. Echániz-AvilesG. Parra-RojasI. Ramírez-PeraltaA. Castro-AlarcónN. Characterization of Staphylococcus epidermidis clinical isolates from hospitalized patients with bloodstream infection obtained in two time periods.PeerJ202210e1403010.7717/peerj.14030 36213498
     [Google Scholar]
  30. MuldrewK.L. TangY.W. LiH. StrattonC.W. Clonal dissemination of Staphylococcus epidermidis in an oncology ward.J. Clin. Microbiol.200846103391339610.1128/JCM.00115‑08 18685001
     [Google Scholar]
  31. NguyenT.H. ParkM.D. OttoM. Host response to Staphylococcus epidermidis colonization and infections.Front. Cell. Infect. Microbiol.201779010.3389/fcimb.2017.00090 28377905
     [Google Scholar]
  32. SicilianoV. PasserottoR.A. ChiuchiarelliM. LeanzaG.M. OjettiV. Difficult-to-treat pathogens: a review on the management of multidrug-resistant Staphylococcus epidermidis.Life (Basel)2023135112610.3390/life13051126 37240771
     [Google Scholar]
  33. VillariP. SarnataroC. IacuzioL. Molecular epidemiology of Staphylococcus epidermidis in a neonatal intensive care unit over a three-year period.J. Clin. Microbiol.20003851740174610.1128/JCM.38.5.1740‑1746.2000 10790091
     [Google Scholar]
  34. EhlersM.M. StrasheimW. LoweM. UeckermannV. KockM.M. Molecular epidemiology of Staphylococcus epidermidis implicated in catheter-related bloodstream infections at an Academic Hospital in Pretoria, South Africa.Front. Microbiol.2018941710.3389/fmicb.2018.00417 29563910
     [Google Scholar]
  35. BothA. HuangJ. QiM. LausmannC. WeißelbergS. BüttnerH. LeziusS. FaillaA.V. ChristnerM. SteggerM. GehrkeT. BaigS. CitakM. AlawiM. AepfelbacherM. RohdeH. Distinct clonal lineages and within-host diversification shape invasive Staphylococcus epidermidis populations.PLoS Pathog.2021172e100930410.1371/journal.ppat.1009304 33544760
     [Google Scholar]
  36. EspadinhaD. SobralR.G. MendesC.I. MéricG. SheppardS.K. CarriçoJ.A. de LencastreH. MiragaiaM. Distinct phenotypic and genomic signatures underlie contrasting pathogenic potential of Staphylococcus epidermidis clonal lineages.Front. Microbiol.201910197110.3389/fmicb.2019.01971 31507574
     [Google Scholar]
  37. FerreiraR.B.R. FerreiraM.C.S. GlatthardtT. SilvérioM.P. ChamonR.C. SalgueiroV.C. GuimarãesL.C. AlvesE.S. dos SantosK.R.N. Osmotic stress induces biofilm production by Staphylococcus epidermidis isolates from neonates.Diagn. Microbiol. Infect. Dis.201994433734110.1016/j.diagmicrobio.2019.02.009 30885396
     [Google Scholar]
  38. LeeJ.Y.H. MonkI.R. Gonçalves da SilvaA. SeemannT. ChuaK.Y.L. KearnsA. HillR. WoodfordN. BartelsM.D. StrommengerB. LaurentF. DodémontM. DeplanoA. PatelR. LarsenA.R. KormanT.M. StinearT.P. HowdenB.P. Global spread of three multidrug-resistant lineages of Staphylococcus epidermidis.Nat. Microbiol.20183101175118510.1038/s41564‑018‑0230‑7 30177740
     [Google Scholar]
  39. KanaiH. SatoH. TakeiY. Community-acquired methicillin-resistant Staphylococcus epidermidis pyelonephritis in a child:] A case report.J. Med. Case Reports20148141510.1186/1752‑1947‑8‑415 25488491
     [Google Scholar]
  40. Vidal OliverL. Bayo CalduchP. Forqué RodríguezL. Navarro OrtegaD. Duch SamperA.M. Colomina RodríguezJ. Methicillin-resistant Staphylococcus epidermidis infectious keratitis: Clinical and microbiological profile.Rev. Esp. Quimioter.202235217117710.37201/req/128.2021 35067009
     [Google Scholar]
  41. GraffunderE.M. VeneziaR.A. Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials.J. Antimicrob. Chemother.2002496999100510.1093/jac/dkf009 12039892
     [Google Scholar]
  42. WatkinsR.R. DavidM.Z. SalataR.A. Current concepts on the virulence mechanisms of meticillin-resistant Staphylococcus aureus.J. Med. Microbiol.20126191179119310.1099/jmm.0.043513‑0 22745137
     [Google Scholar]
  43. OttoM. MRSA virulence and spread.Cell. Microbiol.201214101513152110.1111/j.1462‑5822.2012.01832.x 22747834
     [Google Scholar]
  44. BeshiruA. IgbinosaI.H. AkinnibosunO. OgofureA.G. Dunkwu-OkaforA. UwhubaK.E. IgbinosaE.O. Characterization of resistance and virulence factors in livestock-associated methicillin-resistant Staphylococcus aureus.Sci. Rep.20241411323510.1038/s41598‑024‑63963‑3 38853154
     [Google Scholar]
  45. KotB. PiechotaM. JakubczakA. GryzińskaM. WiteskaM. GrużewskaA. BaranK. DenkiewiczP. The prevalence of virulence determinants in methicillin-resistant Staphylococcus aureus isolated from different infections in hospitalized patients in Poland.Sci. Rep.2022121547710.1038/s41598‑022‑09517‑x 35361858
     [Google Scholar]
  46. AbebeA. BirhanuA. Methicillin resistant Staphylococcus aureus: molecular mechanisms underlying drug resistance development and novel strategies to combat.Infect. Drug Resist.2023167641766210.2147/IDR.S428103 38111667
     [Google Scholar]
  47. PeacockS.J. PatersonG.K. Mechanisms of methicillin resistance in Staphylococcus aureus.Annu. Rev. Biochem.201584157760110.1146/annurev‑biochem‑060614‑034516 26034890
     [Google Scholar]
  48. ChanB.K. AbedonS.T. Loc-CarrilloC. Phage cocktails and the future of phage therapy.Future Microbiol.20138676978310.2217/fmb.13.47 23701332
     [Google Scholar]
  49. SaubolleM.A. Antimicrobial resistance: Current status and future direction.Am. J. Rhinol.200620666767110.2500/ajr.2006.20.2953 17181115
     [Google Scholar]
  50. HouZ. XuB. LiuL. YanR. ZhangJ. YinJ. LiP. WeiJ. Prevalence, drug resistance, molecular typing and comparative genomics analysis of MRSA strains from a tertiary A hospital in Shanxi Province, China.Front. Microbiol.202314127339710.3389/fmicb.2023.1273397 37808303
     [Google Scholar]
  51. DalalV. DhankharP. SinghV. SinghV. RakhaminovG. Golemi-KotraD. KumarP. Structure-based identification of potential drugs against FmtA of Staphylococcus aureus: Virtual screening, molecular dynamics, MM-GBSA, and QM/MM.Protein J.202140214816510.1007/s10930‑020‑09953‑6 33421024
     [Google Scholar]
  52. EnrightM.C. RobinsonD.A. RandleG. FeilE.J. GrundmannH. SprattB.G. The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA).Proc. Natl. Acad. Sci. USA200299117687769210.1073/pnas.122108599 12032344
     [Google Scholar]
  53. GillS.R. FoutsD.E. ArcherG.L. MongodinE.F. DeBoyR.T. RavelJ. PaulsenI.T. KolonayJ.F. BrinkacL. BeananM. DodsonR.J. DaughertyS.C. MadupuR. AngiuoliS.V. DurkinA.S. HaftD.H. VamathevanJ. KhouriH. UtterbackT. LeeC. DimitrovG. JiangL. QinH. WeidmanJ. TranK. KangK. HanceI.R. NelsonK.E. FraserC.M. Insights on evolution of virulence and resistance from the complete genome analysis of an early methicillin-resistant Staphylococcus aureus strain and a biofilm-producing methicillin-resistant Staphylococcus epidermidis strain.J. Bacteriol.200518772426243810.1128/JB.187.7.2426‑2438.2005 15774886
     [Google Scholar]
  54. SilvaV. AlmeidaL. GaioV. CercaN. ManageiroV. CaniçaM. CapeloJ.L. IgrejasG. PoetaP. Biofilm formation of multidrug-resistant MRSA strains isolated from different types of human infections.Pathogens202110897010.3390/pathogens10080970 34451434
     [Google Scholar]
  55. BloemendaalA.L.A. BrouwerE.C. FluitA.C. Methicillin resistance transfer from Staphylocccus epidermidis to methicillin-susceptible Staphylococcus aureus in a patient during antibiotic therapy.PLoS One201057e1184110.1371/journal.pone.0011841 20686601
     [Google Scholar]
  56. HowdenB.P. DaviesJ.K. JohnsonP.D.R. StinearT.P. GraysonM.L. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.Clin. Microbiol. Rev.20102319913910.1128/CMR.00042‑09 20065327
     [Google Scholar]
  57. ChambersH.F. DeLeoF.R. Waves of resistance: Staphylococcus aureus in the antibiotic era.Nat. Rev. Microbiol.20097962964110.1038/nrmicro2200 19680247
     [Google Scholar]
  58. HashemianS.M. FarhadiT. GanjparvarM. Linezolid: A review of its properties, function, and use in critical care.Drug Des. Devel. Ther.2018121759176710.2147/DDDT.S164515 29950810
     [Google Scholar]
  59. MendesR.E. FarrellD.J. SaderH.S. FlammR.K. JonesR.N. Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010-13).J. Antimicrob. Chemother.201570249850410.1093/jac/dku421 25362568
     [Google Scholar]
  60. MirzaeiR. YousefimashoufR. ArabestaniM.R. SedighiI. AlikhaniM.Y. The issue beyond resistance: Methicillin-resistant Staphylococcus epidermidis biofilm formation is induced by subinhibitory concentrations of cloxacillin, cefazolin, and clindamycin.PLoS One20221711e027728710.1371/journal.pone.0277287 36350834
     [Google Scholar]
  61. QianW. LiX. YangM. LiuC. KongY. LiY. WangT. ZhangQ. Relationship between antibiotic resistance, biofilm formation, and biofilm-specific resistance in Escherichia coli isolates from Ningbo, China.Infect. Drug Resist.2022152865287810.2147/IDR.S363652 35686192
     [Google Scholar]
  62. RatherM.A. GuptaK. MandalM. Microbial biofilm: Formation, architecture, antibiotic resistance, and control strategies.Braz. J. Microbiol.20215241701171810.1007/s42770‑021‑00624‑x 34558029
     [Google Scholar]
  63. Skiba-KurekI. NowakP. EmpelJ. TomczakM. KlepackaJ. Sowa-SierantI. ŻakI. PomiernyB. KarczewskaE. Evaluation of biofilm formation and prevalence of multidrug-resistant strains of Staphylococcus epidermidis isolated from neonates with sepsis in southern Poland.Pathogens202110787710.3390/pathogens10070877 34358027
     [Google Scholar]
  64. Farajzadeh SheikhA. Asareh Zadegan DezfuliA. NavidifarT. Samei FardS. DehdashtianM. Association between biofilm formation, structure and antibiotic resistance in Staphylococcus epidermidis isolated from neonatal septicemia in southwest Iran.Infect. Drug Resist.2019121771178210.2147/IDR.S204432 31303772
     [Google Scholar]
  65. RahimiF. Molecular characteristics of biofilm-producing methicillin-resistant Staphylococcus epidermidis isolates causing urinary tract infections.Arch. Clin. Infect. Dis.2018136e6170410.5812/archcid.61704
     [Google Scholar]
  66. XuY. DhaouadiY. StoodleyP. RenD. Sensing the unreachable: challenges and opportunities in biofilm detection.Curr. Opin. Biotechnol.202064798410.1016/j.copbio.2019.10.009 31766008
     [Google Scholar]
  67. ZhaoA. SunJ. LiuY. Understanding bacterial biofilms: From definition to treatment strategies.Front. Cell. Infect. Microbiol.202313113794710.3389/fcimb.2023.1137947 37091673
     [Google Scholar]
  68. JiangY. GengM. BaiL. Targeting biofilms therapy: Current research strategies and development hurdles.Microorganisms202088122210.3390/microorganisms8081222 32796745
     [Google Scholar]
  69. McCallB. New fund stimulates the ailing antibiotic pipeline.Lancet Infect. Dis.2020209101710.1016/S1473‑3099(20)30629‑0 32738933
     [Google Scholar]
  70. HatswellA.J. BaioG. BerlinJ.A. IrsA. FreemantleN. Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999–2014.BMJ Open201666e01166610.1136/bmjopen‑2016‑011666 27363818
     [Google Scholar]
  71. JoppiR. BerteleV. VanniniT. GarattiniS. BanziR. Food and drug administration vs european medicines agency: Review times and clinical evidence on novel drugs at the time of approval.Br. J. Clin. Pharmacol.202086117017410.1111/bcp.14130 31657044
     [Google Scholar]
  72. LythgoeM. KrellJ. WarnerJ.L. DesaiA. KhakiA.R. Time intervals between U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) new cancer therapy approvals.J. Clin. Oncol.20213915_suppl.1575157510.1200/JCO.2021.39.15_suppl.1575
     [Google Scholar]
  73. SouqueC. EscuderoJ.A. MacLeanR.C. Integron activity accelerates the evolution of antibiotic resistance.eLife202110e6247410.7554/eLife.62474 33634790
     [Google Scholar]
  74. BassettiM. GiacobbeD.R. VenaA. BrinkA. Challenges and research priorities to progress the impact of antimicrobial stewardship.Drugs Context2019811510.7573/dic.212600 31516534
     [Google Scholar]
  75. FrenchG. Clinical impact and relevance of antibiotic resistance.Adv. Drug Deliv. Rev.200557101514152710.1016/j.addr.2005.04.005 15978698
     [Google Scholar]
  76. MerkerM. TueffersL. VallierM. GrothE.E. SonnenkalbL. UnterwegerD. BainesJ.F. NiemannS. SchulenburgH. Evolutionary approaches to combat antibiotic resistance: opportunities and challenges for precision medicine.Front. Immunol.202011193810.3389/fimmu.2020.01938 32983122
     [Google Scholar]
  77. PalmerA.C. KishonyR. Understanding, predicting and manipulating the genotypic evolution of antibiotic resistance.Nat. Rev. Genet.201314424324810.1038/nrg3351 23419278
     [Google Scholar]
  78. AndersonM. PanteliD. van KesselR. LjungqvistG. ColomboF. MossialosE. Challenges and opportunities for incentivising antibiotic research and development in Europe.Lancet Reg. Health Eur.20233310070510.1016/j.lanepe.2023.100705 37546576
     [Google Scholar]
  79. VonkenL. de BruijnG.J. NoordinkA. KremersS. SchneiderF. Barriers and facilitators of implementation of new antibacterial technologies in patient care: An interview study with orthopedic healthcare professionals at a university hospital.BMC Health Serv. Res.202424144710.1186/s12913‑024‑10878‑4 38594689
     [Google Scholar]
  80. RaadI. CostertonW. SabharwalU. SadlowskiM. AnaissieE. BodeyG.P. Ultrastructural analysis of indwelling vascular catheters: a quantitative relationship between luminal colonization and duration of placement.J. Infect. Dis.1993168240040710.1093/infdis/168.2.400 8335977
     [Google Scholar]
  81. AdalK.A. FarrB.M. Central venous catheter-related infections.A review Nutrition199612320821310.1016/S0899‑9007(96)91126‑0 8798227
     [Google Scholar]
  82. BlairN. PatilP. NguyenD. Paudyal-NepalB. IoremberF. Antibiotic lock solutions as adjunct therapy for catheter-related blood stream infections in pediatric hemodialysis patients.Front Pediatr.202412137989510.3389/fped.2024.1379895 38665376
     [Google Scholar]
  83. KurtipekB. Koca YozgatA. Kanık yüksekS. KaçarD. BayhanT. Gürlek GökçebayD. Özkaya ParlakA. YaralıN. Antibiotic lock therapy for port catheter-related infections of children with acute leukemia.Mediterr. J. Hematol. Infect. Dis.2024161e202407210.4084/MJHID.2024.072 39258176
     [Google Scholar]
  84. SignorinoC. FuscoE. GalliL. ChiappiniE. Effectiveness of antimicrobial lock therapy for the treatment of catheter-related and central-line-associated bloodstream infections in children: A single center retrospective study.Antibiotics (Basel)202312580010.3390/antibiotics12050800 37237703
     [Google Scholar]
  85. GottfredssonM. PerfectJ.R. Fungal infections in cancer patients.Basic Clin. Oncol.200429419450
     [Google Scholar]
  86. GhoshS. Assay for rapid screening of phytochemicals as antimicrobial agents.Am. J. Biochem. Biotechnol.20139181110.3844/ajbbsp.2013.8.11
     [Google Scholar]
  87. KleinschmidtS. HuygensF. FaoagaliJ. RathnayakeI.U. HafnerL.M. Staphylococcus epidermidis as a cause of bacteremia.Future Microbiol.201510111859187910.2217/fmb.15.98 26517189
     [Google Scholar]
  88. LambertM. IDSA guidelines on the treatment of MRSA infections in adults and children.Am. Fam. Physician2011844455463 21322522
     [Google Scholar]
  89. LiuC. BayerA. CosgroveS.E. DaumR.S. FridkinS.K. GorwitzR.J. KaplanS.L. KarchmerA.W. LevineD.P. MurrayB.E. RybakM.J. TalanD.A. ChambersH.F. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.Clin. Infect. Dis.2011523e18e5510.1093/cid/ciq146
     [Google Scholar]
  90. McCannM.T. GilmoreB.F. GormanS.P. Staphylococcus epidermidis device-related infections: Pathogenesis and clinical management.J. Pharm. Pharmacol.200860121551157110.1211/jpp.60.12.0001 19000360
     [Google Scholar]
  91. DuncanL.R. HamedK.A. SmartJ.I. PfallerM.A. FlammR.K. MendesR.E. Ceftobiprole activity against Gram-positive and Gram-negative pathogens causing bone and joint infections in the United States from 2016 to 2020.Diagn. Microbiol. Infect. Dis.2022103311571310.1016/j.diagmicrobio.2022.115713 35598410
     [Google Scholar]
  92. El SolhA.A. Ceftobiprole: A new broad spectrum cephalosporin.Expert Opin. Pharmacother.200910101675168610.1517/14656560903048967 19527192
     [Google Scholar]
  93. FlammR.K. DuncanL.R. HamedK.A. SmartJ.I. MendesR.E. PfallerM.A. Ceftobiprole activity against bacteria from skin and skin structure infections in the United States from 2016 through 2018.Antimicrob. Agents Chemother.2020646e02566e1910.1128/AAC.02566‑19 32179519
     [Google Scholar]
  94. Hernandez-RodriguezP. BaqueroL.P. Combination therapy as a strategy to control infections caused by multi-resistant bacteria: Current review.Curr. Drug Targets202223326026510.2174/1389450122666210614122352 35282814
     [Google Scholar]
  95. CarenaA.A. StryjewskiM.E. Tedizolid (torezolid) for the treatment of complicated skin and skin structure infections.Expert Rev. Clin. Pharmacol.202013657759210.1080/17512433.2020.1774362 32449440
     [Google Scholar]
  96. ShorrA.F. LodiseT.P. CoreyG.R. De AndaC. FangE. DasA.F. ProkocimerP. Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections.Antimicrob. Agents Chemother.201559286487110.1128/AAC.03688‑14 25421472
     [Google Scholar]
  97. BianX. LiN. LiY. ZhuX. YuJ. HuY. YangH. WeiQ. WuX. WangJ. CaoG. WuJ. WangY. ZhangJ. Lefamulin dosing optimization using population pharmacokinetic and pharmacokinetic/pharmacodynamic assessment in Chinese patients with community-acquired bacterial pneumonia.Front. Pharmacol.202415145674110.3389/fphar.2024.1456741 39525637
     [Google Scholar]
  98. PauknerS. MarianoD. DasA.F. MoranG.J. SandrockC. WaitesK.B. FileT.M. Lefamulin in patients with community-acquired bacterial pneumonia caused by atypical respiratory pathogens: pooled results from two phase 3 trials.Antibiotics (Basel)20211012148910.3390/antibiotics10121489 34943700
     [Google Scholar]
  99. ZhanelG.G. DengC. ZelenitskyS. LawrenceC.K. AdamH.J. GoldenA. BerryL. SchweizerF. ZhanelM.A. IrfanN. BayD. Lagacé-WiensP. WalktyA. MandellL. LynchJ.P. KarlowskyJ.A. Lefamulin: A novel oral and intravenous pleuromutilin for the treatment of community-acquired bacterial pneumonia.Drugs202181223325610.1007/s40265‑020‑01443‑4 33247830
     [Google Scholar]
  100. SharafM.H. El-SherbinyG.M. MoghannemS.A. AbdelmonemM. ElsehemyI.A. MetwalyA.M. KalabaM.H. New combination approaches to combat methicillin-resistant Staphylococcus aureus (MRSA).Sci. Rep.2021111424010.1038/s41598‑021‑82550‑4 33608582
     [Google Scholar]
  101. DellitT.H. OwensR.C. McGowanJ.E. GerdingD.N. WeinsteinR.A. BurkeJ.P. HuskinsW.C. PatersonD.L. FishmanN.O. CarpenterC.F. BrennanP.J. BilleterM. HootonT.M. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship.Clin. Infect. Dis.200744215917710.1086/510393 17173212
     [Google Scholar]
  102. PuriB. VaishyaR. VaishA. Antimicrobial resistance: Current challenges and future directions.Med. J. Armed Forces India202410.1016/j.mjafi.2024.07.006
     [Google Scholar]
  103. StryjewskiM.E. GrahamD.R. WilsonS.E. O’RiordanW. YoungD. LentE. CoreyG.R. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms.Antimicrob. Agents Chemother.20144862352236110.1128/AAC.48.6.2352‑2361.2004
     [Google Scholar]
  104. MoranG.J. FangE. CoreyG.R. DasA.F. De AndaC. ProkocimerP. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial.Lancet Infect. Dis.201414869670510.1016/S1473‑3099(14)70737‑6 24909499
     [Google Scholar]
  105. CoreyG.R. KablerH. MehraP. GuptaS. OvercashJ.S. PorwalA. GiordanoP. LucastiC. PerezA. GoodS. JiangH. MoeckG. O’RiordanW. Single-dose oritavancin in the treatment of acute bacterial skin infections.N. Engl. J. Med.2014370232180219010.1056/NEJMoa1310422 24897083
     [Google Scholar]
  106. MishraB. ReilingS. ZarenaD. WangG. Host defense antimicrobial peptides as antibiotics: Design and application strategies.Curr. Opin. Chem. Biol.201738879610.1016/j.cbpa.2017.03.014 28399505
     [Google Scholar]
  107. SpellbergB. DaumR. Development of a vaccine against Staphylococcus aureus.Semin. Immunopathol.201234233534810.1007/s00281‑011‑0293‑5 22080194
     [Google Scholar]
/content/journals/aia/10.2174/0122113525388954250603114510
Loading
Methicillin-Resistant Staphylococcus epidermidis (MRSE): An Updated Narrative Review on its Epidemiology, Resistance Mechanisms, and Emerging Treatment Strategies
Anti Infect. Agents 24, E22113525388954 (2026); https://doi.org/10.2174/0122113525388954250603114510
/content/journals/aia/10.2174/0122113525388954250603114510
/content/journals/aia/10.2174/0122113525388954250603114510
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): antimicrobial resistance; biofilm; infection; Methicillin; nosocomial; Staphylococcus epidermidis

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test